Skip to main content
. 2020 Jun 25;11(6):480. doi: 10.1038/s41419-020-2685-8

Fig. 7. HO-1/BMMSCs can upregulate the expression of miR-200b in the intestinal tissue of a rat allogeneic SBTx model and alleviate intestinal injury.

Fig. 7

a The immune rejection score of intestinal histopathology in NS-treated, BMMSCs-treated, and HO-1/BMMSCs-treated SBTx rats (1, 3, 7, and 10 day post surgery, n = 6, median). b, c The proportion of TUNEL (+) cells (shown by black arrows) in intestinal tissue of SBTx rats in each group (Instant, and 1, 3, 7, 10, and 14 day post surgery). d Transmission electron microscopy was used to observe the ultrastructure of intestinal tissue in the above-mentioned groups and Sham group after small bowel transplantation (3 day post surgery). The tight junctions are shown using white arrows. e ZO-1 and HMGB3 proteins in intestinal tissue of rats after SBTx were labeled using immunohistochemistry (3 days after surgery). f, g QRT-PCR was used to detect the relative expression levels of Hmgb3 mRNA in intestinal tissues of rats after small bowel transplantation (fold change relative to the Sham group, f), and the relative expression levels of HMGB3, (cleaved) caspase-3, and ZO-1 were detected using western blotting (3 day post operation, g); h QRT-PCR was used to detect the relative expression level of miR-200b in intestinal tissue of SBTx rats (fold change relative to the Sham group, 3 day post surgery). *P < 0.05. #: the data of NS treatment group could not be analyzed at 14 day post surgery. BMMSCs (BM) Bone marrow mesenchymal stem cells; HMGB3 high mobility group box 3; HO-1 heme oxygenase-1; NS normal saline; qRT-PCR quantitative real-time reverse transcription polymerase chain reaction; SBTx small bowel transplantation; ZO-1 Zona Occludens 1.